A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Recently, we showed that homozygosity for the common 677(C-->T) mutation in the methylenetetrahydrofolate reductase (MTHFR) gene, causing thermolability of the enzyme, is a risk factor for neural-tube defects (NTDs). We now report on another mutation in the same gene, the 1298(A-->C) mutation, which changes a glutamate into an alanine residue. This mutation destroys an MboII recognition site and has an allele frequency of .33. This 1298(A-->C) mutation results in decreased MTHFR activity (one-way analysis of variance [ANOVA] P < .0001), which is more pronounced in the homozygous than heterozygous state. Neither the homozygous nor the heterozygous state is associated with higher plasma homocysteine (Hcy) or a lower plasma folate concentration-phenomena that are evident with homozygosity for the 677(C-->T) mutation. However, there appears to be an interaction between these two common mutations. When compared with heterozygosity for either the 677(C-->T) or 1298(A-->C) mutations, the combined heterozygosity for the 1298(A-->C) and 677(C-->T) mutations was associated with reduced MTHFR specific activity (ANOVA P < .0001), higher Hcy, and decreased plasma folate levels (ANOVA P <.03). Thus, combined heterozygosity for both MTHFR mutations results in similar features as observed in homozygotes for the 677(C-->T) mutation. This combined heterozygosity was observed in 28% (n =86) of the NTD patients compared with 20% (n =403) among controls, resulting in an odds ratio of 2.04 (95% confidence interval: .9-4.7). These data suggest that the combined heterozygosity for the two MTHFR common mutations accounts for a proportion of folate-related NTDs, which is not explained by homozygosity for the 677(C-->T) mutation, and can be an additional genetic risk factor for NTDs.

[1]  D. Weir,et al.  Are common mutations of cystathionine β‐synthase involved in the aetiology of neural tube defects? , 1997, Clinical genetics.

[2]  H. Blom,et al.  Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? , 1995, The Lancet.

[3]  M. den Heyer,et al.  Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida , 1995, The Lancet.

[4]  A. Copp,et al.  The embryonic development of mammalian neural tube defects , 1990, Progress in Neurobiology.

[5]  A. Czeizel,et al.  Prevention of the First Occurrence of Neural-Tube Defects by Periconceptional Vitamin Supplementation , 1992 .

[6]  H. Blom,et al.  Is the common 677C-->T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. , 1997, QJM : monthly journal of the Association of Physicians.

[7]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[8]  A. Viel,et al.  Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas. , 1997, British Journal of Cancer.

[9]  S. S. Kang,et al.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. , 1988, American journal of human genetics.

[10]  H. Blom,et al.  Three Different Methods for the Determination of Total Homocysteine in Plasma , 1995, Annals of clinical biochemistry.

[11]  D C Shields,et al.  A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. , 1995, QJM : monthly journal of the Association of Physicians.

[12]  D. Weir,et al.  Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. , 1993, The Quarterly journal of medicine.

[13]  H. Blom,et al.  Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? , 1994, Metabolism: clinical and experimental.

[14]  H. Blom,et al.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. , 1995, American journal of human genetics.

[15]  Prevention of neural tube defects: Results of the Medical Research Council vitamin study , 1991 .

[16]  J. Mills,et al.  Homocysteine metabolism in pregnancies complicated by neural-tube defects , 1995, The Lancet.

[17]  F. Nieto,et al.  The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[18]  E. Mariman,et al.  Altered folate and vitamin B12 metabolism in families with spina bifida offspring. , 1997, QJM : monthly journal of the Association of Physicians.

[19]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[20]  E. Mariman,et al.  Decreased methylene tetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring , 1996, Journal of Molecular Medicine.

[21]  R. Chambers,et al.  Role of thrombin in pulmonary fibrosis , 1995, The Lancet.

[22]  H. Blom,et al.  Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. , 1997, QJM : monthly journal of the Association of Physicians.

[23]  J. Mills,et al.  Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radioassay and microbiological assays. , 1998, Clinical chemistry.